Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.
Joensuu
H
H
Department of Oncology, Helsinki University Central Hospital, Finland.
Roberts
P J
PJ
Sarlomo-Rikala
M
M
Andersson
L C
LC
Tervahartiala
P
P
Tuveson
D
D
Silberman
S
S
Capdeville
R
R
Dimitrijevic
S
S
Druker
B
B
Demetri
G D
GD
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D019788:Fluorodeoxyglucose F18; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors*; D006801:Humans; D000068877:Imatinib Mesylate; D008113:Liver Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000556:secondary; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D010879:Piperazines / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000627:therapeutic use*; D012509:Sarcoma / Q000175:diagnosis / Q000188:drug therapy* / Q000556:secondary; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017154:Stromal Cells; D014055:Tomography, Emission-Computed
D000970:Antineoplastic Agents; D001549:Benzamides; D004791:Enzyme Inhibitors; D010879:Piperazines; D011743:Pyrimidines; D019788:Fluorodeoxyglucose F18; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl